fbpx

14th Annual Congress on Controversies in Ophthalmology

(COPHy) taking place in Lisbon, Portugal, March 24-25, 2023

Get more info

Feb 1, 2022

FDA approves Vabysmo for treatment of wet AMD, DME

The FDA has approved Vabysmo for the treatment of wet age-related macular degeneration and diabetic macular edema, according to a press release from Genentech.

Vabysmo (faricimab-svoa) is an injectable eye medicine that works by targeting and inhibiting Ang-2 and VEGF-A pathways.

 

“Vabysmo represents an important step forward for ophthalmology. It is the first bispecific antibody approved for the eye and a major advance in treating retinal conditions such as wet AMD and diabetic macular edema,” Charles C. Wykoff, MD, PhD, director of research at Retina Consultants of Texas in Houston and a Vabysmo phase 3 investigator, said in the release. “With Vabysmo, we now have the opportunity to offer patients a medicine that could improve their vision, potentially lowering treatment burden with fewer injections over time.”

The approval is based on positive results from four phase 3 studies investigating the therapy’s efficacy and safety in patients with wet AMD and DME. In the first year, patients treated with Vabysmo at intervals spanning up to 4 months experienced noninferior vision gains compared with patients treated every 2 months with aflibercept…….

Read more: https://www.healio.com/news/ophthalmology/20220131/fda-approves-vabysmo-for-treatment-of-wet-amd-dme?utm_source=selligent&utm_medium=email&utm_campaign=news&M_BT=214789326967

Source: Healio

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.